SCHEMBL23701465

SCHEMBL23701465

COc1ccc(N2C[C@H]3CN(C(=O)NC4CCCCC4)C[C@H]3C2)cc1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.74
MAPT P10636 3/20 0.74
GFER P55789 2/20 0.74
KDM4E B2RXH2 2/20 0.52
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
EPHX2 P34913 3/20 0.51
EPHX1 P07099 1/20 0.51
ALDH1A1 P00352 3/20 0.51
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
POLB P06746 1/20 0.51
PKM P14618 1/20 0.51
HPGD P15428 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
CNR1 P21554 1/20 0.49
CNR2 P34972 1/20 0.49
TSHR P16473 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23701466 1.00 SMN1; SMN2 (0.74) SMN1; SMN2MAPTGFERKDM4ENPC1
SCHEMBL27400036 0.86 SMN1; SMN2 (0.54) SMN1; SMN2MAPTGFERKDM4ENPC1
SCHEMBL23701433 0.80 SMN1; SMN2 (0.55) SMN1; SMN2MAPTGFERKDM4ERAB9A
SCHEMBL23701410 0.80 SMN1; SMN2 (0.55) SMN1; SMN2MAPTGFERKDM4ERAB9A
SCHEMBL23701411 0.80 SMN1; SMN2 (0.55) SMN1; SMN2MAPTGFERKDM4ERAB9A
SCHEMBL23701416 0.79 CHRNB2 (0.48) SMN1; SMN2MAPTGFERKDM4ENPC1
SCHEMBL23701418 0.79 CHRNB2 (0.48) SMN1; SMN2MAPTGFERKDM4ENPC1
SCHEMBL23701453 0.77 ACACB (0.47) SMN1; SMN2MAPTGFERALDH1A1KMT2A
SCHEMBL23701451 0.77 ACACB (0.47) SMN1; SMN2MAPTGFERALDH1A1KMT2A
SCHEMBL23701378 0.77 POLB (0.46) SMN1; SMN2MAPTGFERKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-06-25 US disclosed
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-06-25 US disclosed
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-06-25 US disclosed
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-08-05 US disclosed
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors LOX, LOXL1, LOXL3 SMN1; SMN2 3383/4885MAPT 4829/4885GFER 783/4885
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS LOX, LOXL1, LOXL3 SMN1; SMN2 3383/4885MAPT 4829/4885GFER 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.